FDA recall, , High risk
Baxter Cefazolin in Dextrose Injection
Cefazolin in Dextrose Injection may contain particulate matter, which can cause pulmonary emboli, blood vessel occlusions, and phlebitis.
Summary by Recall Canary from the FDA notice
What happened
Particulate matter, identified as cardboard, was found in the solution. The use of the defective product has a reasonable probability of causing pulmonary emboli, occlusions of blood vessels, and phlebitis. To date, no adverse events have been reported.
3 photos
What to do
If a code on your package is listed below:
- Immediately discontinue use of and return all affected units in accordance with your facility’s process.
- For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.
Is yours affected?
Match the lot code, best-by or expiration date and NDC listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
2G3508
- NDC
- 0338-3508-41
- Lot code
- LD175708
- Best-by or expiration date
- 14-Feb-2027
From the FDA notice
The affected lots can be identified by locating the lot number and expiration date on the front of the product package and the label attached to the carton, as shown in the images below.
Recall details
- Company announced
- Sold in
The impacted product was distributed from 3/25/2025 to 6/30/2025 in the United States.
- Company
- BAXTER
- Hazard
- Foreign object
- Risk
High risk
There is a reasonable chance that taking it could cause serious health problems or death.
FDA Class I recall · How risk is rated
